+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 31 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating new treatment approaches for advanced ovarian cancer in people whose tumors are non-HRD positive. This study aims to find out if adding sacituzumab tirumotecan sac-TMT, a targeted therapy, as maintenance treatmentwith or without bevacizumabhelps patients live longer without their cancer worsening compared to standard care. This is a phase 3 randomized study involving participants who have completed surgery and first-line platinum-based chemotherapy. Participants receive sac-TMT intravenously on days 1, 15, and 29 of every 6-week cycle until their disease worsens or they experience prohibitive side effects. Some may also receive bevacizumab intravenously on days 1 and 22 every 6 weeks for up to 22 cycles, depending on the investigators choice. The comparison group receives either bevacizumab alone on the same schedule or is observed closely without maintenance treatment. During the study, participants will have regular evaluations to monitor their cancer status and quality of life. Researchers will measure progression-free survival for up to about 49 months and assess overall survival, adverse events, treatment discontinuation, and changes in quality of life scores for up to 78 months. Participants health will be followed long-term to understand treatment effects and safety over time.

Age: 18Years +FEMALEPhase 3
167 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of targeted therapies and immunotherapy, either alone or in combination, for patients with metastatic colorectal cancer mCRC whose tumors test positive for specific biomarkers. This open-label, Phase 11b study enrolls participants into different treatment groups based on their biomarker test results to explore personalized treatment approaches. Participants receive various combinations of study drugs, including oral medications like inavolisib and divarasib and intravenous infusions such as cetuximab, bevacizumab, atezolizumab, tiragolumab, SY-5609, FOLFOX, and FOLFIRI chemotherapy. Treatment cycles vary from 21 to 28 days depending on the assigned treatment arm, with dosing schedules including daily oral medications and infusions given weekly, every two weeks, or every three weeks. Some treatment arms are closed or not recruiting, while others remain active. Throughout the study, participants undergo regular assessments including tumor imaging to measure response, blood tests, and biomarker sampling. Researchers monitor outcomes such as objective response rate, disease control, duration of response, and adverse events over approximately 84 months. Participants overall health and tumor status are closely followed to evaluate treatment effects and safety during and after therapy.

Age: 18Years +All GendersPhase 1
84 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.

Age: 18Years +All GendersPhase 3
317 locations
R

Actively Recruiting

The trial investigates treatments for adults with KRASNRAS and BRAF wild-type recurrent, unresectable, or metastatic colorectal cancer who have previously undergone chemotherapy. It compares how long participants live without disease progression and overall survival when treated with two different combinations of chemotherapy and targeted biological agents. This phase 3 study explores differences in outcomes between the use of amivantamab plus FOLFIRI chemotherapy and cetuximab or bevacizumab plus FOLFIRI chemotherapy. Participants are randomly assigned to one of two groups. One group receives amivantamab together with FOLFIRI, a chemotherapy regimen including 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan. The other group receives either cetuximab or bevacizumab with the same FOLFIRI chemotherapy. Treatments are given in 28-day cycles and continue until disease progression is observed on scans or other stopping criteria are met. During the study, participants undergo regular monitoring including radiographic scans to assess disease status and progression-free survival for up to 2 years and overall survival for over 4 years. Researchers also evaluate tumor response rates, duration and time to response, quality of life through questionnaires, side effects, and laboratory tests. The total study duration may extend up to more than 4 years to thoroughly assess treatment outcomes and safety.

Age: 18Years +All GendersPhase 3
251 locations
R

Actively Recruiting

This clinical trial is designed to compare the duration participants remain free of disease progression when treated with two different combinations of therapies for adults with KRASNRAS and BRAF wild-type unresectable or metastatic left-sided colorectal cancer. The study focuses on how amivantamab combined with chemotherapy compares to cetuximab combined with chemotherapy in treating this specific cancer type. Participants will be divided into two groups. One group receives amivantamab combined with chemotherapy, either mFOLFOX6 containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and oxaliplatin or FOLFIRI containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan hydrochloride. The other group receives cetuximab combined with the same chemotherapy options. Treatments are given in 28-day cycles and continue until the cancer progresses or other reasons require stopping the treatment. Throughout the study, participants will undergo regular evaluations to monitor how long they remain without disease progression, assessed by independent review and investigators. Other assessments include overall survival, response rates, duration of response, quality of life questionnaires, and safety monitoring up to several years. The study spans several years, with primary outcomes measured up to over four years and additional follow-up extending beyond seven years to gather comprehensive data on treatment effects and patient well-being.

Age: 18Years +All GendersPhase 3
239 locations
P

Actively Recruiting

Researchers are evaluating the combination of fruquintinib and FOLFIRI as a second-line treatment for adults with metastatic colorectal cancer mCRC. This open-label Phase II trial focuses on assessing the effectiveness and safety of this combination in participants previously treated with first-line therapies including oxaliplatin, fluoropyrimidine, and bevacizumab. The study excludes those with certain genetic mutations and aims to enroll up to 60 participants. Participants will receive fruquintinib orally for 21 days followed by a 7-day break in each 28-day cycle. Concurrently, they will receive FOLFIRI intravenously every 2 weeks within each cycle. Treatment continues until disease progression or unacceptable side effects. The FOLFIRI regimen includes irinotecan, leucovorin, and 5-fluorouracil, with possible adjustment to the 5-fluorouracil bolus based on prior treatment tolerance. During the study, participants will be closely monitored with assessments every two cycles 56 days including progression-free survival evaluation, response rates, duration of response, disease control, and overall survival. Safety is tracked through adverse event monitoring from consent to 30 days after treatment ends, up to one year. The total study duration for each participant may last up to two years to fully capture treatment outcomes and safety data.

Age: 18Years +All GendersPhase 2
14 locations
R

Actively Recruiting

Researchers are evaluating treatments for participants with metastatic colorectal cancer mCRC who have previously received irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab. The study aims to compare overall survival when using precemtabart tocentecan Precem-TcT alone, Precem-TcT combined with bevacizumab, and trifluridinetipiracil FTD-TPI plus bevacizumab. This Phase 3 trial addresses the unmet need for effective treatment options in this patient group. Participants will be randomly assigned to one of three groups Precem-TcT alone given intravenously every 3 weeks on Day 1 of each 21-day cycle Precem-TcT combined with bevacizumab administered intravenously every 3 weeks or every 2 weeks depending on the cycle or FTD-TPI tablets taken orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle along with bevacizumab. The study evaluates these treatments over cycles lasting up to an average of 19 months. During the study, participants will undergo various assessments including survival monitoring, disease progression checks, response evaluations using RECIST criteria, adverse event tracking, and quality of life questionnaires. Blood samples will be collected at specific times to measure drug concentrations and immune response markers. Researchers will assess physical functioning and health status repeatedly until treatment ends, with safety and treatment effects monitored throughout the trial period.

Age: 18Years +All GendersPhase 3
92 locations
P

Actively Recruiting

Researchers are investigating the efficacy and safety of golcadomide combined with rituximab compared to investigators choice treatments in adults with relapsed or refractory follicular lymphoma who have received at least one prior systemic therapy. This multicenter, randomized, open-label Phase 3 study focuses on participants with confirmed follicular lymphoma that has returned or not responded to previous treatments, aiming to better understand treatment options in this setting. Participants will be randomly assigned to receive either golcadomide plus rituximab or one of the investigators chosen regimens, which may include rituximab combined with lenalidomide, R-CHOP chemotherapy rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisoneprednisolone, or rituximab with bendamustine. Each treatment involves specified doses on specified days, and the study compares these approaches over a treatment period. During the study, participants will be closely monitored through evaluations such as imaging scans, pathology reviews, and quality of life questionnaires. Researchers will assess progression-free survival up to approximately 32 months, along with other measures like overall response rate, overall survival, duration of response, and minimal residual disease status. Safety and treatment effects will be tracked, and participants may be followed for up to nearly seven years to gather comprehensive outcome data.

Age: 18Years +All GendersPhase 3
160 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations

1-10 of 31

1